Onkologie, Hämatologie - Daten und Informationen

Literatur zu Kapitel 8.3: Stammzelltransplantation

Autor/en: M. Bornhäuser, J. Kienast
Letzte Änderung: 01.07.2008
  • Anasetti C et al.
    Are matched unrelated donor transplants justified for AML in CR1?
    Best Pract Res Clin Haematol 2006;19:321-328.

  • Aversa F et al.
    Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
    J Clin Oncol 2005;23:3447-3454.

  • Ball ED et al.
    Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up.
    Bone Marrow Transplant 2000;25:823-829.

  • Bensinger WI et al.
    Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
    N Engl J Med 2001;344:175-181.

  • Buchner T et al.
    Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
    J Clin Oncol 2006;24:2480-2489.

  • Burnett AK et al.
    Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties.
    Lancet 1998;351:700-708.

  • Cassileth PA et al.
    Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
    N Engl J Med 1998;339:1649-1656.

  • Chalandon Y et al.
    Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
    Biol Blood Marrow Transplant 2002;8:435-443.

  • Collisson EA et al.
    Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission.
    Leukemia 2003;17:2183-2188.

  • Craddock C et al.
    Biology and management of relapsed acute myeloid leukaemia.
    Br J Haematol 2005;129:18-34.

  • de Botton S et al.
    Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
    J Clin Oncol 2005;23:120-126.

  • de Lima M et al.
    Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
    Blood 2004;104:865-872.

  • Drobyski WR.
    The role of allogeneic transplantation in high-risk acute myelogenous leukemia.
    Leukemia 2004;18:1565-1568.

  • Eyrich M et al.
    A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors.
    Br J Haematol 2001;114:422-432.

  • Farag SS et al.
    Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    J Clin Oncol 2005;23:482-493.

  • Giralt S et al.
    Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
    Blood 1997;89:4531-4536.

  • Gorin NC.
    Marrow purging: present status and future perspectives - efficacy in AML.
    Prog Clin Biol Res 1992;377:251-262.

  • Gorin NC et al.
    Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT).
    Leukemia 1991;5:896-904.

  • Hegenbart U et al.
    Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.
    J Clin Oncol 2006;24:444-453.

  • Heldal D et al.
    Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints.
    Bone Marrow Transplant 2002;29:479-486.

  • Jourdan E et al.
    One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
    Br J Haematol 2005;129:403-410.

  • Kolb HJ et al.
    Tolerance and chimerism.
    Transplantation 2003;75:26-31.

  • Kolb HJ et al.
    Graft-versus-leukemia reactions in allogeneic chimeras.
    Blood 2004;103:767-776.

  • Kroger N et al.
    Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Bone Marrow Transplant 2000;26:711-716.

  • Lang P et al.
    A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study.
    Klin Pädiatr 2005;217:334-338.

  • Lashkari A et al.
    Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
    Biol Blood Marrow Transplant 2006;12:466-471.

  • Li L et al.
    Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
    Cancer Immunol Immunother 2005;54:685-693.

  • Miller JS et al.
    Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
    Blood 2005;105:3051-3057.

  • Park KD et al.
    In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive Cord Blood lymphocytes.
    Blood 2006;108(5):1770-1773.

  • Platzbecker U et al.
    Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia.
    Leukemia 2006;20:707-714.

  • Rocha V et al.
    Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.
    N Engl J Med 2004;351:2276-2285.

  • Scheffold C et al.
    Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis.
    Leukemia 2004;18:2048-2050.

  • Schmid C et al.
    Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation.
    Leukemia 2004;18:1430-1433.

  • Slavin S et al.
    Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
    Blood 1998;91:756-763.

  • Socie G et al.
    Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
    Blood 2001;98:3569-3574.

  • Stelljes M et al.
    Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Blood 2005;106:3314-3321.

  • Storb R et al.
    Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.
    Blood 1997;89:3048-3054.

  • Suciu S et al.
    Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.
    Blood 2003;102:1232-1240.

  • Thiede C et al.
    Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers.
    Leukemia 2001;15:293-302.

  • Thiede C et al.
    Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
    Blood 2002;99:4326-4335.

  • Wong R et al.
    Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
    Biol Blood Marrow Transplant 2005;11:108-114.

  • Yanada M et al.
    Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis.
    Cancer 2005;103:1652-1658.

Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag" (Publikation als Buch)
Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
und in Kooperation mit "Studien-Allianz Leukämie"
Deutscher Ärzte-Verlag  Studien-Allianz Leukämien
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch: